@article{3347826,
    title = "Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR–Preserved trial",
    author = "Pocock, S.J. and Ferreira, J.P. and Packer, M. and Zannad, F. and Filippatos, G. and Kondo, T. and McMurray, J.J.V. and Solomon, S.D. and Januzzi, J.L. and Iwata, T. and Salsali, A. and Butler, J. and Anker, S.D.",
    journal = "European Journal of Heart Failure",
    year = "2022",
    volume = "24",
    number = "10",
    pages = "1869-1878",
    publisher = "John Wiley and Sons Ltd",
    doi = "10.1002/ejhf.2607",
    keywords = "amino terminal pro brain natriuretic peptide;  biological marker;  empagliflozin;  placebo;  troponin T;  biological marker;  brain natriuretic peptide;  insulin derivative;  peptide fragment, age distribution;  aged;  Article;  cardiovascular mortality;  chronic obstructive lung disease;  clinical practice;  cohort analysis;  controlled study;  disease marker;  heart failure with preserved ejection fraction;  heart left ventricle ejection fraction;  hospitalization;  human;  major clinical study;  morbidity;  mortality;  mortality risk;  New York Heart Association class;  outcome assessment;  prognosis;  quality of life;  chronic disease;  chronic obstructive lung disease;  heart failure;  heart left ventricle function;  heart stroke volume;  prognosis, Biomarkers;  Chronic Disease;  Heart Failure;  Humans;  Insulins;  Natriuretic Peptide, Brain;  Peptide Fragments;  Prognosis;  Pulmonary Disease, Chronic Obstructive;  Stroke Volume;  Ventricular Function, Left",
    abstract = "Aims: Biomarker-driven prognostic models incorporating N-terminal pro-B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) in heart failure (HF) with preserved ejection fraction (HFpEF) are lacking. We aimed to generate a biomarker-driven prognostic tool for patients with chronic HFpEF enrolled in EMPEROR-Preserved. Methods and results: Multivariable Cox regression models were created for (i) the primary composite outcome of HF hospitalization or cardiovascular death, (ii) all-cause death, (iii) cardiovascular death, and (iv) HF hospitalization. PARAGON-HF was used as a validation cohort. NT-proBNP and hs-cTnT were the dominant predictors of the primary outcome, and in addition, a shorter time since last hospitalization, New York Heart Association (NYHA) class III or IV, history of chronic obstructive pulmonary disease (COPD), insulin-treated diabetes, low haemoglobin, and a longer time since HF diagnosis were key predictors (eight variables, all p < 0.001). The consequent primary outcome risk score discriminated well (c-statistic = 0.75) with patients in the top 10th of risk having an event rate >22× higher than those in the bottom 10th. A model for HF hospitalization alone had even better discrimination (c = 0.79). Empagliflozin reduced the risk of cardiovascular death or hospitalization for HF in patients across all risk levels. NT-proBNP and hs-cTnT were also the dominant predictors of all-cause and cardiovascular mortality followed by history of COPD, low albumin, older age, left ventricular ejection fraction ≥50%, NYHA class III or IV and insulin-treated diabetes (eight variables, all p < 0.001). The mortality risk model had similar discrimination for all-cause and cardiovascular mortality (c-statistic = 0.72 for both). External validation provided c-statistics of 0.71, 0.71, 0.72, and 0.72 for the primary outcome, HF hospitalization alone, all-cause death, and cardiovascular death, respectively. Conclusions: The combination of NT-proBNP and hs-cTnT along with a few readily available clinical variables provides effective risk discrimination both for morbidity and mortality in patients with HFpEF. A predictive tool-kit facilitates the ready implementation of these risk models in routine clinical practice. © 2022 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology."
}